Intraoperative photodynamic treatment for high-grade gliomas

Glioblastoma (GBM) is the most common primary brain tumor. Its incidence is estimated at 5 to 7 new cases each year for 100 000 inhabitants. Despite reference treatment, including surgery, radiation oncology and chemotherapy, GBM still has a very poor prognosis (median survival of 15 months). Because of a systematic relapse of the tumor, the main challenge is to improve local control. In this context, PhotoDynamic Therapy (PDT) may offer a new treatment modality. GBM recurrence mainly occurs inside the surgical cavity borders. Thus, a new light applicator was designed for delivering light during a PDT procedure on surgical cavity borders after Fluorescence Guided Resection. This device combines an inflatable balloon and a light source. Several experimentations (temperature and impermeability tests, homogeneity of the light distribution and ex-vivo studies) were conducted to characterize the device. An abacus was created to determine illumination time from the balloon volume in order to reach a therapeutic fluence value inside the borders of the surgical cavity. According to our experience, cavity volumes usually observed in the neurosurgery department lead to an acceptable average lighting duration, from 20 to 40 minutes. Thus, extra-time needed for PDT remains suitable with anesthesia constraints. A pilot clinical trial is planned to start in 2017 in our institution. In view of the encouraging results observed in preclinical or clinical, this intraoperative PDT treatment can be easily included in the current standard of care.

[1]  C. Wirtz,et al.  Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival , 2015, PloS one.

[2]  Jörg-Christian Tonn,et al.  Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. , 2011, Journal of neurosurgery.

[3]  Ronald Sroka,et al.  Protoporphyrin IX Fluorescence and Photobleaching During Interstitial Photodynamic Therapy of Malignant Gliomas for Early Treatment Prognosis , 2013, Lasers in surgery and medicine.

[4]  B. Wilson,et al.  Photo-Dynamic Therapy: Cavitary Photo-Illumination of Malignant Cerebral Tumours Using a Laser Coupled Inflatable Balloon , 1985, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[5]  M. Scorsetti,et al.  Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study , 2016, Journal of Neuro-Oncology.

[6]  C. Marosi,et al.  Survival and prognostic factors of patients with unresectable glioblastoma multiforme , 2003, Anti-cancer drugs.

[7]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[8]  Kevin Petrecca,et al.  Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma , 2012, Journal of Neuro-Oncology.

[9]  Satish Krishnamurthy,et al.  Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors , 2000 .

[10]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[11]  Jiro Akimoto,et al.  Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas. , 2012, Photodiagnosis and photodynamic therapy.

[12]  M Brada,et al.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  B. Wilson,et al.  Instrumentation and light dosimetry for intra-operative photodynamic therapy (PDT) of malignant brain tumours. , 1986, Physics in medicine and biology.

[14]  Jochen Herms,et al.  Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report , 2008, Journal of Neuro-Oncology.

[15]  B. Chauffert,et al.  Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma , 2016, Cancer medicine.

[16]  K. Hess,et al.  Adult glioma incidence trends in the United States, 1977–2000 , 2004, Cancer.

[17]  Harry T. Whelan,et al.  Evaluation of Photodynamic Therapy near Functional Brain Tissue in Patients with Recurrent Brain Tumors , 2004, Journal of Neuro-Oncology.

[18]  Hiroshi Iseki,et al.  Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. , 2013, Journal of neurosurgery.

[19]  Brian C Wilson,et al.  Photodynamic therapy of brain tumors—A work in progress , 2006, Lasers in surgery and medicine.

[20]  R. Anderson,et al.  Optical integrating balloon device for photodynamic therapy , 2000, Lasers in surgery and medicine.

[21]  S. Eljamel,et al.  The effects of PDT in primary malignant brain tumours could be improved by intraoperative radiotherapy. , 2012, Photodiagnosis and photodynamic therapy.

[22]  H Stepp,et al.  Interstitial Photodynamic Therapy of Brain Tumors , 2010, IEEE Journal of Selected Topics in Quantum Electronics.

[23]  S. Stylli,et al.  Photodynamic therapy of cerebral glioma – A review Part II – Clinical studies , 2006, Journal of Clinical Neuroscience.

[24]  Sam Eljamel,et al.  In vitro light distributions from intracranial PDT balloons. , 2007, Photodiagnosis and photodynamic therapy.

[25]  Andreas Obermeier,et al.  Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5‐aminolevulinic acid induced protoporphyrin IX , 2007, Lasers in surgery and medicine.

[26]  Brian C. Wilson,et al.  Photodynamic therapy of malignant brain tumours , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[27]  M. Sam Eljamel,et al.  ALA and Photofrin® Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial , 2008, Lasers in Medical Science.